BridgeBio doses first participant in ASCEND-ATTR Phase 3b/4 study
BridgeBio said the first participant was dosed in its Phase 3b/4 ASCEND-ATTR study evaluating acoramidis on disease regression in ATTR-CM.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.